AU2007243252B2 - An isolated DNA fragment of the SPARC human promoter and its use - Google Patents

An isolated DNA fragment of the SPARC human promoter and its use Download PDF

Info

Publication number
AU2007243252B2
AU2007243252B2 AU2007243252A AU2007243252A AU2007243252B2 AU 2007243252 B2 AU2007243252 B2 AU 2007243252B2 AU 2007243252 A AU2007243252 A AU 2007243252A AU 2007243252 A AU2007243252 A AU 2007243252A AU 2007243252 B2 AU2007243252 B2 AU 2007243252B2
Authority
AU
Australia
Prior art keywords
gene
cells
sequence
promoter
sparc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007243252A
Other languages
English (en)
Other versions
AU2007243252A1 (en
Inventor
Eduardo Gustavo Alfredo Cafferata
Maria Veronica Lopez
Osvaldo Luis Podhajcer
Diego Luis Viale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Nacional de Investigaciones Científicas y Técnicas
Fundacion Instituto Leloir
Original Assignee
FUNDACION INST LELOIR
Consejo Nacional de Investigaciones Científicas y Técnicas
Fundacion Instituto Leloir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FUNDACION INST LELOIR, Consejo Nacional de Investigaciones Científicas y Técnicas, Fundacion Instituto Leloir filed Critical FUNDACION INST LELOIR
Publication of AU2007243252A1 publication Critical patent/AU2007243252A1/en
Assigned to FUNDACION INSTITUTO LELOIR, CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET) reassignment FUNDACION INSTITUTO LELOIR Request for Assignment Assignors: INIS BIOTECH LLC.
Application granted granted Critical
Publication of AU2007243252B2 publication Critical patent/AU2007243252B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007243252A 2006-04-28 2007-04-26 An isolated DNA fragment of the SPARC human promoter and its use Ceased AU2007243252B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ARP060101724A AR053246A1 (es) 2006-04-28 2006-04-28 Un fragmento aislado de adn del promotor humano de sparc y su uso para dirigir la expresion de un gen heterologo en celulas tumorales
ARP060101724 2006-04-28
PCT/US2007/010196 WO2007127347A2 (en) 2006-04-28 2007-04-26 An isolated dna fragment of the sparc human promoter and its use

Publications (2)

Publication Number Publication Date
AU2007243252A1 AU2007243252A1 (en) 2007-11-08
AU2007243252B2 true AU2007243252B2 (en) 2013-06-20

Family

ID=38006653

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007243252A Ceased AU2007243252B2 (en) 2006-04-28 2007-04-26 An isolated DNA fragment of the SPARC human promoter and its use

Country Status (9)

Country Link
US (1) US8436160B2 (enExample)
EP (1) EP2048954B1 (enExample)
JP (1) JP5215290B2 (enExample)
AR (1) AR053246A1 (enExample)
AT (1) ATE550943T1 (enExample)
AU (1) AU2007243252B2 (enExample)
ES (1) ES2384736T3 (enExample)
NZ (1) NZ572350A (enExample)
WO (1) WO2007127347A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2304281B1 (es) * 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
US9056133B2 (en) * 2011-05-25 2015-06-16 Cti-S.A. Pharmaceutical kit and method for treating cancer
US11542526B2 (en) 2019-02-21 2023-01-03 Unleash Immuno Oncolytics, Inc. Oncolytic adenoviral vector and methods of use
CA3183673A1 (en) 2020-06-26 2021-12-30 Robert Allen Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000072679A1 (en) * 1999-05-28 2000-12-07 University Of Virginia Patent Foundation Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues
WO2005017183A2 (en) * 2003-06-24 2005-02-24 Johns Hopkins University Methylated gene biomarkers for detecting cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772993A (en) * 1997-01-21 1998-06-30 The University Of Virginia Patent Foundation Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
ATE498358T1 (de) 2005-06-29 2011-03-15 Compumedics Ltd Sensoranordnung mit leitfähiger brücke

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000072679A1 (en) * 1999-05-28 2000-12-07 University Of Virginia Patent Foundation Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues
WO2005017183A2 (en) * 2003-06-24 2005-02-24 Johns Hopkins University Methylated gene biomarkers for detecting cancer

Also Published As

Publication number Publication date
WO2007127347A3 (en) 2008-01-03
EP2048954A2 (en) 2009-04-22
JP5215290B2 (ja) 2013-06-19
NZ572350A (en) 2011-12-22
JP2009535031A (ja) 2009-10-01
US8436160B2 (en) 2013-05-07
EP2048954B1 (en) 2012-03-28
AR053246A1 (es) 2007-04-25
WO2007127347A2 (en) 2007-11-08
ES2384736T3 (es) 2012-07-11
EP2048954A4 (en) 2009-12-02
ATE550943T1 (de) 2012-04-15
US20090312401A1 (en) 2009-12-17
AU2007243252A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
JP6375273B2 (ja) 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体
US7048920B2 (en) Recombinant oncolytic adenovirus for human melanoma
JP2017212995A (ja) タンパク質を条件的に発現するベクター
WO2018171103A1 (zh) 可编程的溶瘤病毒疫苗系统及其应用
KR20130015270A (ko) 종양 특이적 프로모터 및 이를 포함하는 종양살상 바이러스 벡터
JP2023014163A (ja) 腫瘍を標的にする合成アデノウイルスおよびその使用
JP2022535169A (ja) 脂質代謝を調節する複製腫瘍溶解性アデノウイルス及びその応用
US7491525B2 (en) Specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it
JPWO2002010368A1 (ja) 腫瘍特異的プロモーター
US8436160B2 (en) Isolated DNA fragment of the SPARC human promoter and its use for driving the expression of an heterologous gene in tumor cells
Liu et al. Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L
EP1601772B1 (en) Modified tert promoter with enhanced tumor-specificity and strength and recombinant vector comprising the same
Li et al. Enhancement of antiangiogenic effects of human canstatin with a hypoxia-regulated transgene vector in lung cancer model
JP2003504316A (ja) 疾患を処置するためのアデノウイルスベクター
EP1662004A1 (en) Method of efficiently constructing growth regulatory recombinant adenovirus vector and kit for the construction thereof
KR100969171B1 (ko) 종양 특이적 발현이 개선된 유전자전달체
EP3812465A1 (en) Adenovirus comprising a modified adenovirus hexon protein
US8188252B2 (en) Rad51 derived cancer cell specific promoters for targeted anti-cancer therapy
JP6913930B2 (ja) 扁平上皮癌に対する抗腫瘍剤
CN109207431B (zh) 一种抑制人癌基因STAT3的α亚型表达的方法
KR100760320B1 (ko) 임포틴 α유전자 및 재조합 ｐ５３ 유전자를 발현하는 재조합 벡터를 포함하는 항암 조성물
WO2026003069A1 (en) Constructs and vectors for reprogramming cells to cdc1 cells, compositions and methods thereof
CN115651932A (zh) 一种靶向消化道肿瘤双靶向溶瘤腺病毒的构建方法及其应用
Lee hTERT or AFP promoter specific expression of HSV-tk induces apoptosis in tumor cells
KR20020063452A (ko) 임포틴 α유전자 및/또는 재조합 ｐ５３ 유전자를포함하는 항암제

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: FUNDACION INSTITUTO LELOIR; CONSEJO NACIONAL DE IN

Free format text: FORMER APPLICANT(S): INIS BIOTECH LLC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired